Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Apr;12(4):1055-1064.
doi: 10.1007/s13555-022-00695-0. Epub 2022 Mar 14.

Impact of Psoriatic Disease on Quality of Life: Interim Results of a Global Survey

April Armstrong  1 , Barbra Bohannan  2 , Sicily Mburu  3 , Ivette Alarcon  4 , Torben Kasparek  4 , Jihen Toumi  5 , Susan Frade  4 , Silvia Fernandez Barrio  6 , Matthias Augustin  7
Affiliations

Impact of Psoriatic Disease on Quality of Life: Interim Results of a Global Survey

April Armstrong et al. Dermatol Ther (Heidelb). 2022 Apr.

Abstract

Introduction: Psoriatic disease (PsD) is a chronic systemic disorder affecting numerous body areas, including skin and joints. Patients' perspectives regarding understanding their disease and dialogue with healthcare professionals (HCPs) on treatment strategies is becoming increasingly important in the holistic management of PsD. The study aim was to determine patients' understanding of the systemic nature of psoriasis and psoriatic arthritis (PsA) and the associated burden of living with these diseases. The relationship between patient and HCP was also evaluated.

Methods: Psoriasis and Beyond: The Global Psoriatic Disease Survey was a cross-sectional, quantitative online survey, conducted in patients with moderate to severe plaque psoriasis with or without concomitant PsA. Here, we report interim analysis results.

Results: A total of 1678 respondents from 11 countries were included. Overall, 31% of patients with psoriasis reported concomitant PsA, 80% of whom considered their PsA severity as moderately or highly active. In total, 63% of patients had heard the term "psoriatic disease". Few patients were aware of psoriasis manifestations (PsA, 29%; axial symptoms, 18%) or comorbidities (obesity, 21%; cardiovascular disease, 18%). Among patients with psoriasis and concomitant PsA, 70% reported swollen and tender joints, especially of the finger(s) and/or toe(s). Most patients (84%) experienced stigma and discrimination and reported a negative impact of their disease on work, emotions, and relationships. Overall, 42% of patients had never discussed treatment goals with their HCP. Patients who were dissatisfied with their current treatment (psoriasis, 15%; psoriasis with PsA, 14%) reported incomplete relief of skin symptoms (57%) and joint symptoms (45%) as primary reasons for dissatisfaction.

Conclusions: Despite many patients having heard the term "psoriatic disease", the majority were unaware of the systemic nature and increased risk of comorbidities associated with PsD. This interim analysis highlights the need for patient education, productive patient-HCP dialogue, and shared decision-making in optimal disease management.

Keywords: Patients’ perspective; Psoriasis; Psoriatic arthritis; Psoriatic disease; Survey; Systemic inflammation.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Proportion of patients aware of the manifestations related to psoriatic disease (i) and associated comorbidities (ii). *Question addressed to patients with psoriasis only
Fig. 2
Fig. 2
Treatment goals aligned with HCP (i) and patients’ personal treatment goals (ii). HCP, healthcare professional. *Question addressed to patients with psoriasis and psoriatic arthritis
Fig. 3
Fig. 3
Treatments currently received by patients with psoriasis (i) and psoriasis with psoriatic arthritis* (ii). Impact of the COVID-19 pandemic on treatment (iii) among patients with psoriasis or psoriatic arthritis and reasons for treatment dissatisfaction provided by dissatisfied patients with psoriasis or psoriatic arthritis (iv). COVID-19, coronavirus 2019. *Question addressed to patients with psoriasis along with psoriatic arthritis
See this image and copyright information in PMC

References

    1. Reich K, Warren RB, Coates LC, Di Comite G. Long-term efficacy and safety of secukinumab in the treatment of the multiple manifestations of psoriatic disease. J Eur Acad Dermatol Venereol. 2020;34:1161–1173. doi: 10.1111/jdv.16124. - DOI - PubMed
    1. Lebwohl MG, Bachelez H, Barker J, et al. Patient perspectives in the management of psoriasis: results from the population-based Multinational Assessment of Psoriasis and Psoriatic Arthritis Survey. J Am Acad Dermatol. 2014;70(871–81):e1–30. - PubMed
    1. Lebwohl MG, Kavanaugh A, Armstrong AW, Van Voorhees AS. US perspectives in the management of psoriasis and psoriatic arthritis: patient and physician results from the population-based multinational assessment of psoriasis and psoriatic arthritis (MAPP) survey. Am J Clin Dermatol. 2016;17:87–97. doi: 10.1007/s40257-015-0169-x. - DOI - PMC - PubMed
    1. Gisondi P, Girolomoni G. Patients' perspectives in the management of psoriasis: the Italian results of the Multinational Assessment of Psoriasis and Psoriatic Arthritis (MAPP) survey. J Dermatolog Treat. 2017;28:390–393. doi: 10.1080/09546634.2016.1255308. - DOI - PubMed
    1. Sumpton D, Kelly A, Tunnicliffe DJ, et al. Patients' perspectives and experience of psoriasis and psoriatic arthritis: a systematic review and thematic synthesis of qualitative studies. Arthritis Care Res (Hoboken) 2020;72:711–722. doi: 10.1002/acr.23896. - DOI - PubMed